A case of sintilimab-induced SJS/TEN:Dermatologic adverse reactions associated with programmed cell death protein-1 inhibitors

Dermatol Ther. 2022 Sep;35(9):e15663. doi: 10.1111/dth.15663. Epub 2022 Jul 6.

Authors

Ying Huang¹, Lin Zhu¹, Xiaoying Ma², Yiyong Hong¹, Xiangyang Su¹, Wei Lai¹, Zijian Gong¹

Affiliations

¹ Department of Dermatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
² Department of Oncology, Guangzhou Mordern Hospital, Guangzhou, China.

PMID: 35739068
DOI: 10.1111/dth.15663

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Apoptosis Regulatory Proteins
Humans
Immune Checkpoint Inhibitors*
Stevens-Johnson Syndrome*

Substances

Antibodies, Monoclonal, Humanized
Apoptosis Regulatory Proteins
Immune Checkpoint Inhibitors
sintilimab